Pediatrix: Vanguard now reports 0% ownership

Pediatrix Medical Group, Inc. (MD) received an amended Schedule 13G/A from The Vanguard Group reporting that it now holds 0 shares of Pediatrix common stock, representing 0% of the class, with no voting or dispositive power.

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. (MD) received an amended Schedule 13G/A from The Vanguard Group reporting that it now holds 0 shares of Pediatrix common stock, representing 0% of the class, with no voting or dispositive power.

The Vanguard Group explains that, following an internal realignment on January 12, 2026 and in reliance on SEC Release No. 34-39538, certain subsidiaries or business divisions that previously were aggregated with The Vanguard Group will now report their beneficial ownership separately. The amendment here is stated to be filed solely to correct the issuer’s CIK in a prior amendment, and it does not report any change in beneficial ownership.

Key Figures

Shares beneficially owned: 0 shares Percent of class owned: 0% Internal realignment date: January 12, 2026 +2 more

5 metrics

Shares beneficially owned 0 shares Amount beneficially owned in Pediatrix Medical Group common stock reported by The Vanguard Group

Percent of class owned 0% Percent of Pediatrix Medical Group common stock class reported as beneficially owned

Internal realignment date January 12, 2026 Date The Vanguard Group completed the internal realignment referenced for disaggregated reporting

CUSIP for common stock 58502B106 CUSIP number for Pediatrix Medical Group common stock covered by this Schedule 13G/A

Signature date September 3, 2026 Date the amendment was signed by the authorized signatory

Key Terms

beneficial ownership, dispositive power, SEC Release No. 34-39538, Investment Company Act of 1940

4 terms

beneficial ownership regulatory

"no longer has, or is deemed to have, beneficial ownership over securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power regulatory

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

SEC Release No. 34-39538 regulatory

"in accordance with SEC Release No. 34-39538 (January 12, 1998)"

Investment Company Act of 1940 regulatory

"investment companies registered under the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

FAQ

What ownership in Pediatrix Medical Group (MD) does The Vanguard Group report in this Schedule 13G/A?

The Vanguard Group reports 0 shares of Pediatrix Medical Group common stock, representing 0% of the class, with no sole or shared voting or dispositive power over any shares.

Why did The Vanguard Group file this Amendment No. 13 for Pediatrix Medical Group (MD)?

The amendment is filed solely to correct the issuer CIK that was reported in a previously filed amendment. The filing explicitly states that no change in beneficial ownership is being reported.

What internal changes at The Vanguard Group affect its Pediatrix (MD) reporting?

The Vanguard Group states that on January 12, 2026 it completed an internal realignment. Certain subsidiaries or business divisions will now report beneficial ownership separately, in reliance on SEC Release No. 34-39538.

Does The Vanguard Group still have beneficial ownership of Pediatrix (MD) through its subsidiaries?

The filing states that, in line with SEC Release No. 34-39538, The Vanguard Group is no longer deemed to have beneficial ownership over securities beneficially owned by the realigned subsidiaries and business divisions, which will report on a disaggregated basis.

What does Item 5 in the Pediatrix (MD) Schedule 13G/A say about ownership level?

Item 5 confirms ownership of 5 percent or less of the class. The ownership table lists 0 shares beneficially owned and a 0% ownership percentage for Pediatrix common stock.

Who signed the Pediatrix Medical Group (MD) Schedule 13G/A on behalf of The Vanguard Group?

The amendment is signed by My Trieu-Gatt, identified as Authorized Signatory, Head of Global Fund Administration, dated September 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 01:48 PM Accepted by SEC EDGAR 09/03/2026 - 01:48 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 13)

Pediatrix Medical Group, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

58502B106

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 58502B106

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions. This Amendment is being filed solely to correct the issuer CIK reported in a previously filed Schedule 13G/A. No change in beneficial ownership is being reported.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Pediatrix Medical Group, Inc.
(b)	Address of issuer's principal executive offices: 1301 Concord Terrace, Sunrise, FL, 33323
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 58502B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	My Trieu-Gatt
Name/Title:	Authorized Signatory, Head of Global Fund Administration
Date:	09/03/2026